Summary
- Current Price
- As of today, BMRN price is $67.36, down -1.71% on
- Current Price All-Time High
- BMRN price is currently -55.61% below its historical high of $151.75 set on
- Market Cap
- BMRN current market cap is $13B, up +17.09% over the past 365 days
- PE Ratio
- BMRN current PE ratio is 181.61
- Revenue
- BMRN current annual revenue is $3.24B, up +14.18% year-over-year
- Next Earnings
- The next earnings release for BMRN is on
Profile
| Metric | Value |
|---|---|
| Full Name | BioMarin Pharmaceutical Inc. |
| Ticker | NASDAQ: BMRN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | biomarin.com |
| Employees | 3,040 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $67.36 | |
| Price, 1D Change | -1.71% | |
| Market Cap | $13B | |
| - | ||
| PE Ratio | 181.61 | |
| Beta | 0.35 | |
| Revenue | $3.24B | |
| Revenue, 1Y Change | +14.18% | |
| EPS | $1.80 | |
| EPS, 1Y Change | -18.24% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $1.80 | |
| EPS Estimate | $5.03 | N/A |
| EPS Est. Change | +178.81% | N/A |
| Revenue | $3.24B | |
| Revenue Estimate | $3.91B | N/A |
| Revenue Est. Change | +20.53% | N/A |
| Current Price | $67.36 | |
| Price Target | $86.00 | - |
| Price Tgt. Change | +27.67% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.30 | $2.21 | -33.04% | |
| $3.26 | $1.80 | -44.59% | |
| $5.03 | N/A | +178.81% | |
| $6.63 | N/A | +267.26% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.81B | $2.84B | +0.88% | |
| $3.18B | $3.24B | +1.89% | |
| $3.91B | N/A | +20.53% | |
| $4.46B | N/A | +37.44% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +16.14% | |
| Price, 3Y | -25.40% | |
| Market Cap, 1Y | +17.09% | |
| Market Cap, 3Y | -23.25% | |
| Revenue, 1Y | +14.18% | |
| Revenue, 3Y | +58.33% | |
| EPS, 1Y | -18.24% | |
| EPS, 3Y | +140.88% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $67.36 | |
| SMA 200 | $56.87 | |
| SMA 50 | $59.55 | |
| EMA 200 | $58.04 | |
| EMA 50 | $60.43 | |
| MACD | $2.63 | |
| Beta | 0.35 | |
| ATR | $2.04 | |
| 14-Day RSI | 66.07 | |
| 10-Day Volatility | 48.50% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $3.24B | |
| EPS | $1.80 | |
| Gross Profit | $2.48B | |
| Gross Margin | 77.27% | |
| Operating Income | $533.48M | |
| Operating Margin | 27.52% | |
| Net Income | $348.90M | |
| Net Margin | 10.76% | |
| EBITDA | $613.04M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.10 | |
| 5.21 | ||
| 3.50 | ||
| - | ||
| 4 | ||
| 6.38 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 181.61 | |
| 3.77 | ||
| 2.06 | ||
| 20.67 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $6.09B | |
| $1.56B | ||
| $7.59B | ||
| $3.95B | ||
| $1.51B | ||
| $759.03M | ||
| Total Debt | $597.18M | |
| $8.69M | ||
| $759.03M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $2.87B | ||
| $1.95B | ||
| $736.83M | ||
| $0.00 | ||
| $79.56M | ||
| $0.00 | ||
| $133.58M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $827.99M | ||
| -$414.24M | ||
| -$42.39M | ||
| Capex | $110.98M | |
| $717.02M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Canaccord Genuity | → | |
| Oppenheimer | → | |
| Morgan Stanley | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| RBC Capital | → | |
| Canaccord Genuity | → | |
| Citigroup | ||
| B of A Securities | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
No data
Screeners with BMRN
FAQ
- What is the ticker symbol for BioMarin Pharmaceutical Inc.?
- The ticker symbol for BioMarin Pharmaceutical Inc. is NASDAQ:BMRN
- Does BioMarin Pharmaceutical Inc. pay dividends?
- No, BioMarin Pharmaceutical Inc. does not pay dividends
- What sector is BioMarin Pharmaceutical Inc. in?
- BioMarin Pharmaceutical Inc. is in the Healthcare sector
- What industry is BioMarin Pharmaceutical Inc. in?
- BioMarin Pharmaceutical Inc. is in the Biotechnology industry
- What country is BioMarin Pharmaceutical Inc. based in?
- BioMarin Pharmaceutical Inc. is headquartered in United States
- When did BioMarin Pharmaceutical Inc. go public?
- BioMarin Pharmaceutical Inc. initial public offering (IPO) was on July 26, 1999
- Is BioMarin Pharmaceutical Inc. in the S&P 500?
- No, BioMarin Pharmaceutical Inc. is not included in the S&P 500 index
- Is BioMarin Pharmaceutical Inc. in the NASDAQ 100?
- No, BioMarin Pharmaceutical Inc. is not included in the NASDAQ 100 index
- Is BioMarin Pharmaceutical Inc. in the Dow Jones?
- No, BioMarin Pharmaceutical Inc. is not included in the Dow Jones index
- When was BioMarin Pharmaceutical Inc. last earnings report?
- BioMarin Pharmaceutical Inc.'s most recent earnings report was on August 6, 2026
- When does BioMarin Pharmaceutical Inc. report earnings?
- The next expected earnings date for BioMarin Pharmaceutical Inc. is October 26, 2026
Data Sources & References
- BMRN Official Website www.biomarin.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1048477/000104847726000004/0001048477-26-000004-index.htm
- BMRN Profile on Yahoo Finance finance.yahoo.com/quote/BMRN
- BMRN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bmrn